Worldwide attention is focusing on efforts to stimulate new vaccines, diagnostics, and drugs for diseases of poverty. Here are some highlights of the media coverage BIO Ventures for Global Health has received.
BIO Ventures for Global Health initiatives are making headlines
May 11, 2010
Neglected Diseases, PTV News
Pharma Television
An interview with CEO Melinda Moree on market based incentives designed to engage industry in global health product development.
May 10, 2010
Patent Pool Starts to Attract Interest
SciDev.net
An industry-led 'patent pool', set up last year to target neglected diseases, has finally yielded some fruit. Drug company GlaxoSmithKline (GSK) launched the pool last year, saying the company would make patents for some of its drugs and manufacturing processes freely available and with no-cost licences. Many hoped the move would boost research into neglected diseases.
May 7, 2010
Biotech and Global Health
The Lancet
South Africa's newly created Technology Innovation Agency will be the first African governmental agency, and Massachusetts Institute of Technology the first University, to join the Pool for Open Innovation against neglected tropical diseases (NTDs) created by GlaxoSmithKline to aid in the discovery and development of new medicines for the treatment of 16 NTDs in developing countries.
May 7, 2010
Global Health: MIT And South Africa Sign On To Patent Pool For Neglected Diseases
Chemical & Engineering News
After initially stalling, the Pool for Open Innovation against Neglected Tropical Diseases, a collection of intellectual property (IP) and drug discovery know-how, is gaining traction. At the Biotechnology Industry Organization’s convention in Chicago this week, MIT announced becoming the first university to donate IP to the pool, and South Africa’s Technology Innovation Agency (TIA), a government group that assists biotech firms, said it will use the pool to help develop drugs to treat tuberculosis and malaria.
May 6, 2010
MIT and South African Research Agency Dive into Industry Patent Pool
Nature
The Massachusetts Institute of Technology (MIT) and South Africa’s Technology Innovation Agency have joined a patent pool founded by pharma giant GlaxoSmithKline. Participants in the pool agree to share patents that facilitate research into the tropical diseases that plague the developing world, including malaria and leishmaniasis.
May 5, 2010
MIT Joins Effort to Fight Neglected Tropical Diseases
Boston Globe
The Massachusetts Institute of Technology is the first academic institution to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. The pool is administered by BIO Ventures for Global Health. Previous contributors of intellectual property to the pool include drug and life sciences companies such as GlaxoSmithKline and Cambridge-based Alnylam Pharmaceuticals Inc.
May 5, 2010
South Africa Taps Patent Pool for Neglected Diseases
Reuters
South Africa will use a new "patent pool" to work on new drugs for tuberculosis and malaria, making it the first government to take advantage of the industry-led idea. The pool aims to speed development of drugs for neglected tropical diseases by freely sharing patented information owned by drug companies and academic institutions.
March 17, 2010
Open source: the way forward in the search for new treatments for the infectious diseases of poverty?
TropIKA.net
BIO Ventures for Global Health CEO Melinda Moree offers her opinion of open innovation in this TropIKA.net article, which profiles a new collaboration, called the Open Source Drug Discovery Foundation (OSDD). The partnership plans to use voluntary and open efforts to accelerate the development of affordable drugs for diseases including malaria, leishmaniasis and – first – tuberculosis.
March 1, 2010
Battle Joined: Knowledge Pool Created to Fight Neglected Diseases
Biotech-now.org
This BIOtechNOW blog entry highlights a partnership formed by GlaxoSmithKline and Alnylam Pharmaceuticals to share intellectual property (IP) and industrial know-how to develop new therapies to treat the world’s most neglected tropical diseases. The IP Pool, originally formed in February 2009, will be managed by BIO Ventures for Global Health.
February 23, 2010
Intellectual Property Pool: Podcast with BVGH, Alnylam and GlaxoSmithKline
Biotech-now.org
BVGH CEO Melinda Moree discusses the Intellectual Property (IP) Pool to aid in the development of new treatments for neglected tropical diseases with Alnylam Pharmaceuticals CEO John Maraganore and Nick Cammack, Vice President and head of GlaxoSmithKline’s Tres Cantos Medicines Development Campus. BIO Ventures for Global Health has been selected to administer the IP Pool.
February 4, 2010
Questions as Mileposts of Progress
The Huffington Post
Dr. Orin Levine, Executive Director of the International Vaccine Access Center at Johns Hopkins University, recently discussed with BVGH CEO Melinda Moree how the progress of product-development partnerships should be measured.
January 30, 2010
Gates pledges $10 billion to childhood vaccines
The Seattle Times
The Microsoft co-founder and his wife re-upped for the battle in a big way. The $10 billion, 10-year commitment to childhood vaccines they announced at the World Economic Forum in Davos, Switzerland, ranks as the biggest philanthropic pledge ever to a single cause.
January 27, 2010
Learning to Share
Nature
By opening up its database of potential malaria drugs, GlaxoSmithKline has blazed a path that other pharmaceutical companies should follow.
January 22, 2010
BIO supports joint research efforts for neglected diseases
ThomasNet News
BIO applauds joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases, and selection of BIO Ventures for Global Health as administrator of Intellectual Property Pool. According to BIO President and CEO, Jim Greenwood, BIO strongly endorses IP Pool as a promising tool to foster more collaboration between industry, non-profit organizations, and researchers in developing new therapies.
January 11, 2010
New at the Top: Melinda Moree, Bio Ventures for Global Health
The Washington Post
BVGH CEO Melinda Moree was featured in an interview in The Washington Post, where she discusses her new role at BIO Ventures for Global Health and the need for new drugs, vaccines, and diagnostics for the developing world.
May 1, 2009
Creative Business Solutions to Global Health Issues
Weill Cornell Medical College
Dr. Christopher Earl, BVGH President & CEO, was featured as a panelist at the Cornell Business & Medicine Symposium held in New York on April 30, 2009. The panel addressed why current markets have failed to inspire innovative new medicines for infectious diseases of poverty, and how changing reimbursement practices for physicians might alter the landscape.
April, 2008
Doing Better at Doing Good
Nature Biotechnology
Global health initiatives should place greater emphasis on mechanisms for encouraging small and medium-sized biotech enterprises to participate in the fight against neglected diseases.
March 13, 2008
Voucher Senate Sponsor Seeks New Incentive for Drugmakers
BioWorld Today
The likeability of the U.S. by foreign nations could increase if Americans broadened their efforts in global health initiatives, such as developing drugs to tackle diseases that affect poor populations, said Sen. Sam Brownback (R-Kan.).
March 12, 2008
Priority Review Vouchers the Next 'Golden Ticket'?
BioWorld Today
Political scientists looking for a model to streamline the legislative process might ponder the efforts of a group of Duke University professors.
June 1, 2007
TB Gets Deadlier and Closer
Atlanta Journal Constitution
BVGH's Chris Earl and Joelle Tanguy (Global Business Coalition) join forces on this op-ed about the looming global threat posed by drug-resistant TB.
February 13, 2007
Panel Deliberates Ideas to Fund Global Health Products
BioWorld
BVGH's VP of Business Development, Julie Klim, leads a panel on innovative financing mechanisms for global health products like an investment fund.
February 12, 2007
Creating a $1.5B Market
BioCentury
BVGH's Wendy Taylor discusses the pilot AMC program for pneumococcal vaccines.
February 9, 2007
Vaccinating the World
Business Week
BVGH Founder, Wendy Taylor, discusses the need for market incentives for vaccine development and the importance of the AMC pilot launch.
January 11, 2007
Increased Innovation Needed in the Fight Against Epidemics
Seattle Post-Intelligencer
BVGH CEO, Chris Earl and Board member Melinda Moree, write an Op-ed about the need for increased innovation in response to the White House Summit on Malaria.
January, 2007
Innovation and Reduced Risk Remain Keys to 2007 Funding
BioExecutive International
BVGH CEO, Chris Earl, makes the case for investment in neglected dieseases like TB.
December 29, 2006
NDT Funding Strategies Seek to Bring Bench Progress to Bedside
BioWorld Today
BVGH CEO, Chris Earl, discusses neglected tropical disease funding opportunities.
November 1, 2006
Getting Your Gates
The Scientist
BVGH CEO, Chris Earl, talks about the entrance of non-profits into drug development work.
September 19, 2006
Bets on Biotech
U.S. News & World Report
BVGH CEO, Chris Earl, is quoted in this latest article on biomedical philanthropy.
July 3, 2006
A Market Remedy That Can Bring Vaccines to the Poor
Financial Times
Together with Harvey Bale, Director-General of the International Pharmaceutical Manufacturers and Associations (IFPMA), BVGH CEO, Christopher D. Earl, encourages the G8 to use the St. Petersburg summit to launch a pilot AMC.
June 22, 2005
$5.4M Pledged To Spur Drugs For Diseases That Afflict Poor
USA Today
BVGH's newest grant - a $5.4 million grant from the Bill & Melinda Gates Foundation - is announced.
June 21, 2005
Funds Steer Biotech Drugs to Poor
The Wall Street Journal
BVGH's newest grant - a $5.4 million grant from the Bill & Melinda Gates Foundation - is announced.
March 28, 2005
Third World Solutions
BioCentury
Karen Bernstein looks at the changing landscape of global health product development opportunities and the emerging role biotech companies are playing in this field. The article highlights the work that BVGH is doing to uncover and build market opportunities for products that address neglected diseases.
March 18, 2005
BIO Ventures Pushes Biotech Involvement in Global Issues
BioWorld Today
BVGH's mission and activities are highlighted, as the organization moves into its first full year of operations.
September, 2004
Developing Markets
Nature Biotechnology
Wendy Taylor, Executive Director of BVGH, responds to an August editorial in the September Letters to the Editor section.
August, 2004
Boldness, but with realism
Nature Biotechnology
This editorial applauds BVGH for "daring to conceive that biotech and the developing world can be allies against the scourge of disease" and points out the challenges presented by inadequate distribution systems in resource-poor settings.
June 7, 2004
BIO’s Global Health Venture
BioCentury
The Biotechnology Industry Organization (BIO), together with the Bill & Melinda Gates Foundation and the Rockefeller Foundation, is set to announce the creation of BIO Ventures for Global Health (BVGH).
June 6, 2004
Medical Aid on Way for Poorer Nations
The Washington Post
The Biotechnology Industry Organization (BIO), together with the Bill & Melinda Gates Foundation and the Rockefeller Foundation, is set to announce the creation of BIO Ventures for Global Health (BVGH).
May 28, 2004
Bringing Biotechnology to Developing Countries
BIO News
The Biotechnology Industry Organization (BIO), together with the Bill & Melinda Gates Foundation and the Rockefeller Foundation, is set to announce the creation of BIO Ventures for Global Health (BVGH).